Ulisse Biomed S.p.A. (BIT:UBM)

Italy flag Italy · Delayed Price · Currency is EUR
0.7880
-0.0060 (-0.76%)
Dec 5, 2025, 5:29 PM CET
-1.01%
Market Cap 19.39M
Revenue (ttm) 925.87K
Net Income (ttm) -5.30M
Shares Out 24.48M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,000
Average Volume 120,650
Open 0.7960
Previous Close 0.7940
Day's Range 0.7880 - 0.8000
52-Week Range 0.6800 - 1.4000
Beta 0.80
RSI 34.43
Earnings Date Dec 30, 2025

About Ulisse Biomed

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 22
Stock Exchange Borsa Italiana
Ticker Symbol UBM
Full Company Profile

Financial Performance

In 2024, Ulisse Biomed's revenue was 767,929, an increase of 1059.87% compared to the previous year's 66,208. Losses were -5.94 million, 23.8% more than in 2023.

Financial Statements

News

There is no news available yet.